HitGen

HitGen Deferred Tax Liabilities

The Deferred Tax Liabilities of HitGen (688222.SS) as of Nov 5, 2026 is 19.00 M CNY. In the previous year, Deferred Tax Liabilities was 16.00 M CNY — a change of 18.75% (higher).

Deferred Tax Liabilities

19.00 MCNY

YoY

18.75%

Last updated:

Deferred Tax Liabilities of HitGen is 2024 19.00 M CNY. Deferred Tax Liabilities of HitGen was 2023 16.00 M CNY. It decreases by 18.75% higher compared to the previous year.

The HitGen Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2020
11.80 M CNY
Jan 1, 2021
12.07 M CNY
Jan 1, 2022
12.08 M CNY
Jan 1, 2023
16.00 M CNY
Jan 1, 2024
19.00 M CNY
The HitGen Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
19.00 MCNY+18.75%
16.00 MCNY+32.41%
12.08 MCNY+0.12%
12.07 MCNY+2.29%
11.80 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HitGen Stock analysis

What does HitGen do? HitGen Inc. generates revenue through DEL screening services, DEL library customization, chemical synthesis, and transfer of new drug R&D projects. The company serves pharmaceutical and biotechnology firms seeking to develop seed and lead compounds for drug discovery. Its domestic market focus includes clients in China, while international clients also access its DEL technology solutions. HitGen's services support the research and development phase of drug development, targeting companies in the pharmaceutical sector that require advanced compound libraries for early-stage drug discovery. The firm's DEL technology enables the creation of large compound libraries for high-throughput screening, which is critical for identifying potential drug candidates. HitGen's services are tailored to clients' needs, offering customized DEL libraries and synthesis support for drug development projects. Its business model relies on providing specialized R&D services to pharmaceutical companies that require efficient compound screening and lead optimization. HitGen's offerings include the research and creation of DEL technology, development of hit and lead compounds, and transfer of new drug R&D projects. The company's DEL screening services are a core product, allowing clients to identify promising compounds quickly. By focusing on DEL technology, HitGen positions itself as a key provider of specialized services for drug discovery in both domestic and international markets. HitGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HitGen stock

Deferred Tax Liabilities of HitGen is 19.00 M CNY in 2024.

Deferred Tax Liabilities of HitGen changed from 16.00 M CNY to 19.00 M CNY, representing a 18.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities HitGen since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's HitGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HitGen

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HitGen